Physician profile
Robert L Stokes
NPI 1073541603
$8,273.21
in general payments reported to CMS, 2019-2025
39 companies · $1,324 in 2025
The $1,324 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,060 · 2020: $802 · 2021: $1,114 · 2022: $1,282 · 2023: $1,467 · 2024: $1,224 · 2025: $1,324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,920 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,920.10 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,905.94 | 2019-2025 | Airsupra, Tezspire, Farxiga |
| Novo Nordisk INC | $726.54 | 2019-2025 | Ozempic, Wegovy |
| Pfizer INC. | $694.37 | 2019-2025 | |
| Lilly USA, LLC | $548.88 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Abbvie INC. | $546.93 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $526.68 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $347.32 | 2019-2023 | Arexvy |
| Allergan, INC. | $314.47 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $293.84 | 2019-2023 | Eliquis, Camzyos |
| Abbott Laboratories | $275.58 | 2023-2025 | Freestyle Libre 3, Freestyle Copilot |
| Amgen INC. | $263.24 | 2019-2025 | Otezla, Repatha, Repatha |
| Astellas Pharma US INC | $245.48 | 2021-2025 | Veozah |
| Dexcom, INC. | $182.29 | 2024-2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Madrigal Pharmaceuticals | $145.10 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $127.30 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Stokes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.